Schering-Plough
Executive Summary
Plans $ 111 mil. expansion of Brinny, Ireland plant where Intron A is lyophilized and packaged. Intron A (recombinant alfa interferon) is awaiting FDA approval for treating hepatitis C; the PLA was filed in June 1989. Schering also plans to produce and distribute GM-CSF at Brinny.